Raffaello Ditaranto
Overview
Explore the profile of Raffaello Ditaranto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ditaranto R, Pelletti G, Rossi C, Biffi M, Wilde A, Biagini E, et al.
JACC Case Rep
. 2025 Mar;
30(5):103174.
PMID: 40054899
Cocaine consumption is a significant global problem, with an estimated 20 million users worldwide. Sudden cardiac death is frequently reported in this population, particularly among individuals <40 years of age....
2.
Shiwani H, Davies R, Topriceanu C, Ditaranto R, Owens A, Raman B, et al.
J Am Coll Cardiol
. 2025 Jan;
85(7):685-695.
PMID: 39772357
Background: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death. Current diagnosis emphasizes the detection of left ventricular hypertrophy (LVH) using a fixed threshold of ≥15-mm maximum wall...
3.
Parisi V, Graziosi M, Lopes L, De Luca A, Pasquale F, Tini G, et al.
Eur J Prev Cardiol
. 2024 Nov;
PMID: 39486037
Aims: Left ventricular (LV) ring-like scar on cardiac magnetic resonance (CMR) has been linked to malignant arrhythmias in patients with non-ischemic cardiomyopathy. This study aimed to perform a comprehensive evaluation...
4.
Ditaranto R, Chiti C, Milandri A, Lai F, Lovato L, Graziosi M, et al.
Circ Cardiovasc Imaging
. 2024 Jul;
17(10):e016865.
PMID: 38994576
No abstract available.
5.
Furia A, Ditaranto R, Biagini E, Parisi V, Incensi A, Parisini S, et al.
BMC Neurol
. 2024 Apr;
24(1):113.
PMID: 38580906
Background: Fabry disease is a multisystemic disorder characterized by deposition of globotriaosylceramide (Gb3) and its deacylated form in multiple organs, sometimes localized in specific systems such as the nervous or...
6.
Musumeci B, Tini G, Biagini E, Merlo M, Calore C, Ammirati E, et al.
Int J Cardiol
. 2024 Jan;
400:131784.
PMID: 38242504
Background: A minority of patients with hypertrophic cardiomyopathy (HCM) presents advanced heart failure (HF) during their clinical course, in the context of left ventricular (LV) remodeling with reduced LV ejection...
7.
Bertero E, Chiti C, Schiavo M, Tini G, Costa P, Todiere G, et al.
Eur J Heart Fail
. 2023 Dec;
26(1):59-64.
PMID: 38131253
Aims: In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential...
8.
Cannie D, Syrris P, Protonotarios A, Bakalakos A, Pruny J, Ditaranto R, et al.
Eur Heart J
. 2023 Aug;
44(48):5064-5073.
PMID: 37639473
Background And Aims: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants...
9.
Ditaranto R, Leone O, Lovato L, Niro F, Cenacchi G, Papa V, et al.
JACC Cardiovasc Imaging
. 2023 Aug;
16(12):1629-1632.
PMID: 37542504
No abstract available.
10.
Caponetti A, Accietto A, Saturi G, Ponziani A, Sguazzotti M, Massa P, et al.
Front Cardiovasc Med
. 2023 Mar;
10:1146725.
PMID: 36970351
Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate...